8-K filed Aug 4, 2026 at 06:20 ET
Revvity reported Q2 2026 adjusted EPS of $1.41, a 19.5% beat vs the $1.22 consensus, on revenue of $730M (above $703.2M consensus). The company raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40 and revenue guidance to $2.83-$2.86B, citing strong Diagnostics segment growth (+11% pro forma organic) and tariff refunds. The filing also confirms a definitive agreement to divest the China Immunodiagnostics business for up to $200M, expected to close by end of 2027. The combination of a significant earnings beat, raised guidance, and portfolio simplification is a clear positive catalyst.